ArriVent BioPharma, Inc. (NASDAQ:AVBP) Receives Average Rating of "Moderate Buy" from Analysts

Key Points

• Analyst sentiment is moderately bullish: Eight of ten analysts rate ArriVent BioPharma a “buy,” while one rates it a hold and one a sell. The average 12-month price target is $44.86, well above the stock’s recent $28.90 price.
• Recent performance showed continued losses: ArriVent reported quarterly EPS of negative $1.05, missing the consensus estimate of negative $0.99. Analysts expect a full-year EPS loss of approximately $4.01.
• The company is developing precision oncology treatments, led by furmonertinib for EGFR-mutated non-small cell lung cancer. Institutional investors and hedge funds own 9.48% of the company.

ArriVent BioPharma, Inc. (NASDAQ:AVBP - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the ten analysts that are covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, one has given a hold recommendation and eight have issued a buy recommendation on the company. The average 1 year price target among analysts that have issued a report on the stock in the last year is $44.8571.

Several research analysts recently issued reports on the stock. Truist Financial upped their price target on shares of ArriVent BioPharma from $43.00 to $45.00 and gave the stock a "buy" rating in a research report on Friday, May 29th. HC Wainwright boosted their target price on shares of ArriVent BioPharma from $44.00 to $47.00 and gave the stock a "buy" rating in a research note on Monday, August 17th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of ArriVent BioPharma in a research note on Friday, July 17th. Citigroup reduced their target price on shares of ArriVent BioPharma from $43.00 to $40.00 and set a "buy" rating on the stock in a research report on Thursday, August 13th. Finally, BTIG Research reissued a "buy" rating and set a $42.00 price target on shares of ArriVent BioPharma in a research note on Thursday, August 13th.

ArriVent BioPharma Stock Performance

Shares of AVBP opened at $28.90 on Monday. The stock has a fifty day moving average price of $30.30 and a two-hundred day moving average price of $29.11. ArriVent BioPharma has a 52-week low of $17.00 and a 52-week high of $35.83. The company has a market cap of $1.43 billion, a price-to-earnings ratio of -7.98 and a beta of 1.35.

ArriVent BioPharma (NASDAQ:AVBP - Get Free Report) last announced its earnings results on Wednesday, August 12th. The company reported ($1.05) EPS for the quarter, missing the consensus estimate of ($0.99) by ($0.06). As a group, research analysts predict that ArriVent BioPharma will post -4.01 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of AVBP. Quantbot Technologies LP acquired a new stake in shares of ArriVent BioPharma in the 2nd quarter valued at $59,000. Jupiter Topco LLC acquired a new position in shares of ArriVent BioPharma during the second quarter valued at $226,000. Arizona State Retirement System acquired a new position in shares of ArriVent BioPharma during the second quarter valued at $233,000. Glenmede Trust Co. NA bought a new position in ArriVent BioPharma in the first quarter valued at about $209,000. Finally, The Manufacturers Life Insurance Company bought a new position in ArriVent BioPharma in the first quarter valued at about $209,000. Institutional investors and hedge funds own 9.48% of the company's stock.

About ArriVent BioPharma

ArriVent BioPharma, Inc is a clinical-stage biopharmaceutical company focused on developing precision oncology medicines for patients with genetically defined cancers. The company's strategy is to identify promising therapies that have been developed or clinically validated in other markets and advance them through global development programs.

ArriVent's lead product candidate is furmonertinib, an oral, irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. The company is evaluating furmonertinib as a potential treatment for patients with EGFR-mutated non-small cell lung cancer, including tumors with EGFR exon 20 insertion mutations and other EGFR alterations.

ArriVent obtained exclusive development and commercialization rights for furmonertinib outside China through a collaboration with Allist Pharmaceuticals.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.